Utama › Kanser Paru-paru Bukan Sel Kecil › Alabama › Birmingham
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Birmingham, AL
22 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Birmingham (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Mengambil pesertaFasa 3
- Central Alabama Research ( Site 0108), Birmingham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Mengambil pesertaFasa 3
- Alabama Oncology, Birmingham
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Alabama Oncology, St Vincent's Birmingham, Birmingham
- Alabama Oncology, Brookwood, Birmingham
- Alabama Oncology, Princeton, Birmingham
- dan 5 lagi
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- University of Alabama at Birmingham, Birmingham
Pan-tumor MRD Study
Mengambil pesertaKajian pemerhatian
- Alabama Oncology, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- University of Alabama at Birmingham, Birmingham
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mengambil pesertaFasa 3
- Local Institution - 0347, Birmingham
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Mengambil pesertaFasa 2/3
- Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Mengambil pesertaFasa 1/2
- UAB Medicine - UAB Hospital, Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Mengambil pesertaKajian pemerhatian
- University of Alabama at Birmingham, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Mengambil pesertaFasa 1/2
- The University of Alabama, Birmingham
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Mengambil pesertaFasa 1/2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Mengambil pesertaFasa 1
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Mengambil pesertaFasa 1
- Uni of Alabama at Birmingham, Birmingham
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- dan 1 lagi
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Mengambil pesertaFasa 3
- Central Alabama Research, Birmingham
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Mengambil pesertaFasa 2
- University of Alabama at Birmingham, Birmingham
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Mengambil pesertaFasa 2
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Mengambil peserta
- University of Alabama at Birmingham, Birmingham
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Mengambil pesertaFasa 2
- The University of Alabama at Birmingham Hospital, Birmingham
GEMINI-NSCLC: NSCLC Biomarker Study
Mengambil pesertaKajian pemerhatian
- Alabama Oncology, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Birmingham
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY121 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH57 kajian
- Washington, DC55 kajian
Kajian lain di Birmingham
- Kanser (semua jenis)31 kajian
- Kanser Payudara24 kajian
- Kanser Ovari23 kajian
- Obesiti23 kajian
- Leukemia Mieloid Akut21 kajian
- Mieloma Pelbagai18 kajian
- COPD17 kajian
- Penyakit Kardiovaskular17 kajian
- Diabetes Jenis 216 kajian
- Kanser Endometrium16 kajian
- Berat Badan Berlebihan16 kajian
- Fibrosis Kistik16 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.